Can-Fite BioPharma Ltd. (CANF)
USD 1.33
(-6.34%)
USD 1.33
(-6.34%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 743 Thousand USD | -10.12% |
| 2022 | 810 Thousand USD | -5.04% |
| 2021 | 853 Thousand USD | 11.8% |
| 2020 | 763 Thousand USD | -62.45% |
| 2019 | 2.03 Million USD | -46.81% |
| 2018 | 3.82 Million USD | 352.21% |
| 2017 | 844.74 Thousand USD | 398.38% |
| 2016 | 169.5 Thousand USD | 2.9% |
| 2015 | 164.71 Thousand USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 1.78 Million USD | 0.0% |
| 2012 | - USD | -100.0% |
| 2011 | 468.99 Thousand USD | -37.07% |
| 2010 | 745.21 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 158 Thousand USD | 0.0% |
| 2024 Q1 | 158 Thousand USD | 1.94% |
| 2023 Q4 | 155 Thousand USD | -20.92% |
| 2023 Q2 | 196 Thousand USD | 0.0% |
| 2023 FY | 728 Thousand USD | -10.12% |
| 2023 Q1 | 196 Thousand USD | -0.51% |
| 2023 Q3 | 196 Thousand USD | 0.0% |
| 2022 Q4 | 197 Thousand USD | -3.43% |
| 2022 Q1 | 205 Thousand USD | 0.49% |
| 2022 Q2 | 204 Thousand USD | -0.49% |
| 2022 Q3 | 204 Thousand USD | 0.0% |
| 2022 FY | 810 Thousand USD | -5.04% |
| 2021 Q4 | 204 Thousand USD | -18.73% |
| 2021 FY | 853 Thousand USD | 11.8% |
| 2021 Q1 | 148 Thousand USD | -1.33% |
| 2021 Q2 | 250 Thousand USD | 68.92% |
| 2021 Q3 | 251 Thousand USD | 0.4% |
| 2020 Q3 | 211 Thousand USD | 3.43% |
| 2020 Q4 | 150 Thousand USD | -28.91% |
| 2020 Q1 | 198 Thousand USD | 3.13% |
| 2020 FY | 763 Thousand USD | -62.45% |
| 2020 Q2 | 204 Thousand USD | 3.03% |
| 2019 Q1 | 299 Thousand USD | 3.46% |
| 2019 FY | 2.03 Million USD | -46.81% |
| 2019 Q4 | 192 Thousand USD | -83.33% |
| 2019 Q2 | 389 Thousand USD | 30.1% |
| 2019 Q3 | 1.15 Million USD | 196.14% |
| 2018 Q4 | 289 Thousand USD | -89.01% |
| 2018 FY | 3.82 Million USD | 352.21% |
| 2018 Q2 | 270 Thousand USD | -57.28% |
| 2018 Q3 | 2.62 Million USD | 873.7% |
| 2018 Q1 | 632 Thousand USD | 501.77% |
| 2017 Q2 | 79.4 Thousand USD | 8.17% |
| 2017 Q3 | 586.9 Thousand USD | 639.1% |
| 2017 Q1 | 73.41 Thousand USD | 4264.95% |
| 2017 Q4 | 105.02 Thousand USD | -82.11% |
| 2017 FY | 844.74 Thousand USD | 398.38% |
| 2016 Q2 | 54.39 Thousand USD | -3.91% |
| 2016 FY | 169.5 Thousand USD | 2.9% |
| 2016 Q3 | 60.26 Thousand USD | 10.8% |
| 2016 Q4 | -1762.64 USD | -102.92% |
| 2016 Q1 | 56.6 Thousand USD | 109.44% |
| 2015 Q2 | 71.69 Thousand USD | 0.0% |
| 2015 Q4 | 27.02 Thousand USD | -59.04% |
| 2015 Q3 | 65.99 Thousand USD | -7.96% |
| 2015 FY | 164.71 Thousand USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 FY | - USD | -100.0% |
| 2014 Q1 | - USD | -100.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q4 | 1.78 Million USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | 1.78 Million USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | -100.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 FY | - USD | -100.0% |
| 2011 Q2 | 130.55 Thousand USD | 2.51% |
| 2011 Q4 | 111.43 Thousand USD | -6.44% |
| 2011 Q3 | 119.09 Thousand USD | -8.77% |
| 2011 FY | 468.99 Thousand USD | -37.07% |
| 2011 Q1 | 127.35 Thousand USD | -16.24% |
| 2010 Q3 | 129.5 Thousand USD | 0.0% |
| 2010 Q4 | 152.04 Thousand USD | 17.4% |
| 2010 FY | 745.21 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 160 Thousand USD | -364.375% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 397.2% |
| Armata Pharmaceuticals, Inc. | -29.24 Million USD | 102.541% |
| Actinium Pharmaceuticals, Inc. | -709 Thousand USD | 204.795% |
| Azitra, Inc. | 260.45 Thousand USD | -185.274% |
| Chromocell Therapeutics Corporation | -2.57 Million USD | 128.805% |
| Calidi Biotherapeutics, Inc. | -1.25 Million USD | 159.156% |
| CEL-SCI Corporation | -3.95 Million USD | 118.771% |
| iBio, Inc. | -1.02 Million USD | 172.488% |
| Lineage Cell Therapeutics, Inc. | 8.27 Million USD | 91.02% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | -13.39 Million USD | 105.548% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | 722.826% |
| NovaBay Pharmaceuticals, Inc. | 7.89 Million USD | 90.589% |
| NanoViricides, Inc. | -759.01 Thousand USD | 197.89% |
| Oragenics, Inc. | -15.45 Million USD | 104.808% |
| BiomX Inc. | -1.22 Million USD | 160.505% |
| BiomX Inc. | -1.22 Million USD | 160.505% |
| Protalix BioTherapeutics, Inc. | 42.51 Million USD | 98.252% |
| Palatin Technologies, Inc. | 4.39 Million USD | 83.085% |
| Scorpius Holdings, Inc. | -2.21 Million USD | 133.523% |